NCT07024316View on ClinicalTrials.gov

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

September 1, 2027

Conditions
Congenital Erythropoietic Porphyria (CEP)
Interventions
DRUG

ATL-001 (Ciclopirox oral solution)

Daily administration of oral ATL-001

Sponsors
All Listed Sponsors
lead

Atlas Molecular Pharma

INDUSTRY

NCT07024316 - A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP | Biotech Hunter | Biotech Hunter